Journal article
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: A rapid update
- Abstract:
- The overall aim of the guideline is to provide up‐to‐date, evidence‐based recommendations on the use of biologic therapies targeting TNF (adalimumab, etanercept, certolizumab pegol, infliximab), IL12/23p40 (ustekinumab), IL17A (ixekizumab, secukinumab), IL17RA (brodalumab) and IL23p19 (guselkumab, risankizumab, tildrakizumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 10.5MB, Terms of use)
-
- Publisher copy:
- 10.1111/bjd.19039
Authors
- Publisher:
- Wiley
- Journal:
- British Journal of Dermatology More from this journal
- Volume:
- 183
- Issue:
- 4
- Pages:
- 628-637
- Publication date:
- 2020-03-18
- Acceptance date:
- 2020-03-15
- DOI:
- EISSN:
-
1365-2133
- ISSN:
-
0007-0963
- Language:
-
English
- Keywords:
- Pubs id:
-
1094347
- Local pid:
-
pubs:1094347
- Deposit date:
-
2020-03-16
- ARK identifier:
Terms of use
- Copyright holder:
- British Association of Dermatologists
- Copyright date:
- 2020
- Rights statement:
- © 2020 British Association of Dermatologists.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Wiley at: https://doi.org/10.1111/bjd.19039
If you are the owner of this record, you can report an update to it here: Report update to this record